EGFR and non-small cell lung carcinoma: The use of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) has been approved as a treatment for advanced non-small cell lung carcinoma (NSCLC) with EGFR-activating mutations.